Search - tctmd.com

Displaying 221 - 240 of 688

Sort: Relevancy | Date

News Daily News

Lidocaine Less Likely Than Fentanyl to Blunt P2Y12 Inhibitors in the Cath Lab

L.A. McKeown

September 07, 2021

News Daily News

To Increase Physical Activity, Put Patients In Charge and Make It a Game

Yael L. Maxwell

September 07, 2021

News Daily News

As CDC Moves to Update Contraception Guidance, Cardiologists Should Take Note

Alexandra Dangas

September 06, 2021

News Conference News ESC 2021

In HFrEF, AI Shows Promise For Predicting Beta Blocker Response

Yael L. Maxwell

September 03, 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for August 2021

Shelley Wood

September 03, 2021

News Conference News ESC 2021

New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy

Michael O'Riordan

September 03, 2021

News Conference News ESC 2021

PET Imaging Detects Degeneration After TAVI as Well as Surgical, Native Valves

Yael L. Maxwell

September 02, 2021

News Conference News ESC 2021

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

Shelley Wood

September 02, 2021

News Conference News ESC 2021

No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER

Michael O'Riordan

September 02, 2021

News Conference News ESC 2021

AV Junction Ablation Plus CRT Cuts Deaths in Permanent AF Subset

Todd Neale

September 01, 2021

News Daily News

Genetic Testing for CVD in Children: AHA Statement Suggests Focus on Multidisciplinary Care

Yael L. Maxwell

September 01, 2021

News Conference News ESC 2021

His-bundle Pacing, TAVI Advice Debut in ESC’s Update to Pacing, CRT Guidelines

Todd Neale

September 01, 2021

News Conference News ESC 2021

Both Acute and Chronic Myocardial Injury in COVID-19 Impede 6-Month Survival

Caitlin E. Cox

September 01, 2021

Podcast Heart Sounds

August 2021: Top ESC News With Stephan Achenbach

September 01, 2021

News Opinion CV Team Dispatch

September 2021 News Roundup

L.A. McKeown

September 01, 2021

News Conference News ESC 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

Michael O'Riordan

August 31, 2021

News Conference News ESC 2021

2021 ESC/EACTS Valve Guidelines Unveil TAVI/SAVR Age Cutoffs and Earlier Care

Shelley Wood

August 31, 2021

News Conference News ESC 2021

‘Quadpill’ Beats Monotherapy at BP Lowering: QUARTET

Caitlin E. Cox

August 31, 2021

Presentation ESC 2021

Influenza Vaccination after Myocardial Infarction - a randomized, double-blind, placebo-controlled, multicenter trial

Presenter: Ole Fröbert

August 31, 2021

News Conference News ESC 2021

PRONOUNCE: No Difference in CVD Risks With Degarelix and Leuprolide for Prostate Cancer

Michael O'Riordan

August 30, 2021

Advertisement

Lidocaine Less Likely Than Fentanyl to Blunt P2Y12 Inhibitors in the Cath Lab

To Increase Physical Activity, Put Patients In Charge and Make It a Game

As CDC Moves to Update Contraception Guidance, Cardiologists Should Take Note

In HFrEF, AI Shows Promise For Predicting Beta Blocker Response

TCTMD’s Top 10 Most Popular Stories for August 2021

New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy

PET Imaging Detects Degeneration After TAVI as Well as Surgical, Native Valves

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER

AV Junction Ablation Plus CRT Cuts Deaths in Permanent AF Subset

Genetic Testing for CVD in Children: AHA Statement Suggests Focus on Multidisciplinary Care

His-bundle Pacing, TAVI Advice Debut in ESC’s Update to Pacing, CRT Guidelines

Both Acute and Chronic Myocardial Injury in COVID-19 Impede 6-Month Survival

August 2021: Top ESC News With Stephan Achenbach

September 2021 News Roundup

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

2021 ESC/EACTS Valve Guidelines Unveil TAVI/SAVR Age Cutoffs and Earlier Care

‘Quadpill’ Beats Monotherapy at BP Lowering: QUARTET

Influenza Vaccination after Myocardial Infarction - a randomized, double-blind, placebo-controlled, multicenter trial

PRONOUNCE: No Difference in CVD Risks With Degarelix and Leuprolide for Prostate Cancer

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content